Alan F. List

Research interests

Publications

• Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.02341

• Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1908892

• TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

  Leukemia · 2019 · https://doi.org/10.1038/s41375-018-0351-2

• The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

  Blood · 2019 · https://doi.org/10.1182/blood-2018-10-844654

• Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2015.66.2510

• The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

  Blood · 2016 · https://doi.org/10.1182/blood-2016-07-730556

• Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30627-1

• An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

  Blood · 2015 · https://doi.org/10.1182/blood-2014-10-607341

• STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients

  Blood · 2013 · https://doi.org/10.1182/blood-2013-04-494930

• Induction of myelodysplasia by myeloid-derived suppressor cells

  Journal of Clinical Investigation · 2013 · https://doi.org/10.1172/jci67580

• STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

  Blood · 2012 · https://doi.org/10.1182/blood-2012-06-435297

• Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations

  Blood · 2012 · https://doi.org/10.1182/blood-2011-12-399683

• Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies

  Blood · 2011 · https://doi.org/10.1182/blood-2010-07-295857

• First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.30.5961

• Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A

  Blood · 2011 · https://doi.org/10.1182/blood-2010-10-311019

• Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa0912228

• Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

  Leukemia · 2010 · https://doi.org/10.1038/leu.2010.167

• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

  The Lancet Oncology · 2009 · https://doi.org/10.1016/s1470-2045(09)70003-8

• Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2009.23.7503

• Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2009.23.8329

• A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

  Proceedings of the National Academy of Sciences · 2009 · https://doi.org/10.1073/pnas.0811267106

• Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys

  JNCI Journal of the National Cancer Institute · 2008 · https://doi.org/10.1093/jnci/djn349

• Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

  Blood · 2008 · https://doi.org/10.1182/blood-2008-01-134858

• Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

  Cancer · 2008 · https://doi.org/10.1002/cncr.23697

• The incidence and impact of thrombocytopenia in myelodysplastic syndromes

  Cancer · 2007 · https://doi.org/10.1002/cncr.22602

• Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

  Blood · 2007 · https://doi.org/10.1182/blood-2007-01-068833

• Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

  New England Journal of Medicine · 2006 · https://doi.org/10.1056/nejmoa061292

• Efficacy of Lenalidomide in Myelodysplastic Syndromes

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa041668

• Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

  Blood · 2001 · https://doi.org/10.1182/blood.v98.12.3212

• Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes

  Blood · 2001 · https://doi.org/10.1182/blood.v97.5.1427

• Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

  Journal of Clinical Oncology · 1997 · https://doi.org/10.1200/jco.1997.15.2.433

• Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

  Journal of Clinical Oncology · 1993 · https://doi.org/10.1200/jco.1993.11.9.1652

• Deletion of IRF-1 , Mapping to Chromosome 5q31.1, in Human Leukemia and Preleukemic Myelodysplasia

  Science · 1993 · https://doi.org/10.1126/science.8438156

Current projects

No projects listed.